Michael A Gillette
Overview
Explore the profile of Michael A Gillette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
32478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haines M, Thorup J, Gohsman S, Ctortecka C, Newton C, Rohrer D, et al.
bioRxiv
. 2024 Nov;
PMID: 39605438
Formalin-fixed, paraffin-embedded (FFPE) patient tissues are a valuable resource for proteomic studies with the potential to associate the derived molecular insights with clinical annotations and outcomes. Here we present an...
2.
Petralia F, Ma W, Yaron T, Caruso F, Tignor N, Wang J, et al.
Cell
. 2024 Feb;
187(5):1255-1277.e27.
PMID: 38359819
Despite the successes of immunotherapy in cancer treatment over recent decades, less than <10%-20% cancer cases have demonstrated durable responses from immune checkpoint blockade. To enhance the efficacy of immunotherapies,...
3.
Gillette M, Jimenez C, Carr S
Mol Cell Proteomics
. 2024 Jan;
23(2):100688.
PMID: 38281326
No abstract available.
4.
Wang J, Hong R, Demicco E, Tan J, Lazcano R, Moreira A, et al.
Cell Rep Med
. 2023 Aug;
4(9):101173.
PMID: 37582371
We introduce a pioneering approach that integrates pathology imaging with transcriptomics and proteomics to identify predictive histology features associated with critical clinical outcomes in cancer. We utilize 2,755 H&E-stained histopathological...
5.
Geffen Y, Anand S, Akiyama Y, Yaron T, Song Y, Johnson J, et al.
Cell
. 2023 Aug;
186(18):3945-3967.e26.
PMID: 37582358
Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM...
6.
Li Y, Porta-Pardo E, Tokheim C, Bailey M, Yaron T, Stathias V, et al.
Cell
. 2023 Aug;
186(18):3921-3944.e25.
PMID: 37582357
Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan-cancer analysis uncovers insights into the impacts of...
7.
Abelin J, Bergstrom E, Rivera K, Taylor H, Klaeger S, Xu C, et al.
Nat Commun
. 2023 Apr;
14(1):1851.
PMID: 37012232
Serial multi-omic analysis of proteome, phosphoproteome, and acetylome provides insights into changes in protein expression, cell signaling, cross-talk and epigenetic pathways involved in disease pathology and treatment. However, ubiquitylome and...
8.
Salgia A, Krueger C, Gillette M
Ann Pharmacother
. 2022 Aug;
57(5):544-552.
PMID: 36004393
Background: In patients who received a cardiac stent, practice guidelines recommend dual antiplatelet therapy (DAPT). However, an urgent procedure may be required necessitating interruption of DAPT. Intravenous cangrelor was previously...
9.
Anurag M, Jaehnig E, Krug K, Lei J, Bergstrom E, Kim B, et al.
Cancer Discov
. 2022 Aug;
12(11):2586-2605.
PMID: 36001024
Significance: Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a 19q13.31-33 somatic deletion encoding genes serving lagging-strand DNA synthesis (LIG1, POLD1, and XRCC1),...
10.
Mani D, Krug K, Zhang B, Satpathy S, Clauser K, Ding L, et al.
Nat Rev Cancer
. 2022 Mar;
22(5):298-313.
PMID: 35236940
Genomic analyses in cancer have been enormously impactful, leading to the identification of driver mutations and development of targeted therapies. But the functions of the vast majority of somatic mutations...